DUBLIN--(BUSINESS WIRE)--The "Pharmacovigilance Market Research Report by Type (Contract Outsourcing and In-house), Clinical Trial, Method, End User, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
The Global Pharmacovigilance Market size was estimated at USD 6,669.16 million in 2021, USD 7,637.60 million in 2022, and is projected to grow at a CAGR 15.04% to reach USD 15,458.60 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Pharmacovigilance to forecast the revenues and analyze the trends in each of the following sub-markets:
- Based on Type, the market was studied across Contract Outsourcing and In-house.
- Based on Clinical Trial, the market was studied across Phase I, Phase II, Phase III, Phase IV, and Pre-clinical.
- Based on Method, the market was studied across Cohort Event Monitoring, EHR Mining, Intensified ADR Reporting, Spontaneous Reporting, and Targeted Spontaneous Reporting.
- Based on End User, the market was studied across Academic & Research Institutes, Government Agencies, Health Insurance Companies, Hospitals & Care Providers, and Pharma & Biotech Companies.
- Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Pharmacovigilance Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Market Dynamics
Drivers
- Increase in the Prevalence of Chronic Diseases
- Rise in Pharmacovigilance Applications in Spontaneous Reporting and Electronic Health Record Mining
- Rise in Demand for Outsourcing Services by Players
- Rising Incidence of ADR and Drug Toxicity
Restraints
- High-Cost Technology for Small and Mid-Sized Players
Opportunities
- Emergence of COVID-19 Have Opened New Opportunities
- Rising Investment in Research and Development (R&D) by Healthcare Companies
Challenges
- Lack of Skilled Labor
Key Topics Covered:
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. Pharmacovigilance Market, by Type
7. Pharmacovigilance Market, by Clinical Trial
8. Pharmacovigilance Market, by Method
9. Pharmacovigilance Market, by End-user
10. Americas Pharmacovigilance Market
11. Asia-Pacific Pharmacovigilance Market
12. Europe, Middle East & Africa Pharmacovigilance Market
13. Competitive Landscape
14. Company Usability Profiles
15. Appendix
Companies Mentioned
- Accenture, PLC
- Bristol Myers Squibb
- C.H. Boehringer Sohn AG & Ko. KG
- Capgemini SE
- ClinChoice Inc.
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- HCL Technologies Limited
- ICON PLC
- Infosys Limited
- International Business Machines Corporation
- IQVIA
- ITclinical
- Laboratory Corporation
- Linical Co., Ltd.
- Novartis International AG
- Oracle Corporation
- Parexel International
- Pfizer Inc.
- Quanticate International limited
- Sanofi S.A.
- Take Solutions Ltd.
- Tata Consultancy Services
- Wipro Limited
For more information about this report visit https://www.researchandmarkets.com/r/f9xbjq
